# Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction

> **NCT06652087** · NA · RECRUITING · sponsor: **I.M. Sechenov First Moscow State Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Bacterial Overgrowth Syndrome Small Bowel
- Heart Failure with Preserved Ejection Fraction

## Interventions

- **DRUG:** Rifaximin
- **OTHER:** Standard HFpEF treatment

## Key facts

- **NCT ID:** NCT06652087
- **Lead sponsor:** I.M. Sechenov First Moscow State Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-02
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06652087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06652087, "Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06652087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*